Aarti Drugs Ltd has reported a strong financial performance for the fourth quarter of FY25, with net profit rising 32.7% year-on-year (YoY) to ₹62.9 crore, compared to ₹47.4 crore in the same period last year.
Financial Highlights
- Revenue from operations increased 9.2% YoY to ₹677 crore, up from ₹620 crore in Q4FY24.
- EBITDA rose 8.9% YoY to ₹93.4 crore, compared to ₹85.8 crore in the previous year.
- Operating margins remained steady at 13.8%, reflecting continued cost pressures.
Stock Market Reaction
Ahead of the earnings announcement, Aarti Drugs shares closed 1.87% lower at ₹349 on the BSE.
Industry Outlook
Despite steady revenue growth, the company’s flat margins indicate ongoing cost challenges. Analysts expect pricing adjustments and operational efficiencies to play a key role in future profitability.
